Increased metabolism in the R6/2 mouse model of Huntington's disease. - Wikidata - awgldk - TriplyDB

Increased metabolism in the R6/2 mouse model of Huntington's disease.

Increased metabolism in the R6/2 mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q33301810

about

Early alterations of brain cellular energy homeostasis in Huntington disease models Mouse models of polyglutamine diseases: review and data table. Part I Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease Shaping the role of mitochondria in the pathogenesis of Huntington's disease Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.Proliferative hypothalamic neurospheres express NPY, AGRP, POMC, CART and Orexin-A and differentiate to functional neurons.Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of Huntington's disease.No evidence of impaired gastric emptying in early Huntington's Disease.Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease.Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.Measures of growth in children at risk for Huntington disease Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington's Disease Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models Energy deficit in Huntington disease: why it matters.Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models.Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.Body weight is a robust predictor of clinical progression in Huntington disease.Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease.Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease.Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease.Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.Hypocretin and melanin-concentrating hormone in patients with Huntington disease.Neuropeptide alterations in the infundibular nucleus of Huntington's disease patients.Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease.Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.

P2860

Q23912810-62B5A05A-9A58-440F-AB46-F9D212ABFD50 Q26853025-983533BA-91B8-4B95-9ABA-10A654CF62F2 Q27334872-FD6FAB43-DAE6-424A-B03D-AD240B95E8FB Q28384036-AF15D398-0B6C-4588-8BCB-CE406527AA13 Q28748449-E1201F88-9605-44B3-A625-D0A0DA0685E6 Q30542392-16F63E52-6A7A-46E6-A03B-BD3A7FA1CC13 Q31011157-C5D0BE39-CF93-49FE-A223-E681C904CF51 Q33517121-6DFF9746-D6BD-47E9-AC51-83B8C095E905 Q33935845-C3374631-351A-4873-B00E-2FA40FA529C9 Q34087126-E6BB5A5E-247C-4A5A-9A9F-987616E03A16 Q34459323-C5901591-8D84-4AC9-90D3-7C5F404AB85E Q34520437-C5E25967-5D2E-46E4-B10F-47C6FDF62DF0 Q35058593-C24215AE-EC85-4ACE-9BF8-50F9C321A35D Q35086831-CA65DEEA-1E1C-447B-82C9-E3C75F794AE1 Q35754248-6091A62C-3E3D-41AA-884D-969F7014BCEF Q36093756-2F9AB417-7950-4A0E-B13D-8F0D9FDD3414 Q36149988-6E979507-C23A-4A7B-B174-0494418350E7 Q36234711-89F7041B-3946-4F22-88AB-C6032550B0B7 Q37089398-7A932CD3-84CB-4615-A47A-B5F695354240 Q37112122-A21D79BB-E59A-4F4D-8967-70AC504E8BFA Q37834195-D5FA85BD-E09A-4A49-84D9-C2BD9EADA1B5 Q38235229-A77AB610-D985-4E0E-B76D-E9EE33161A69 Q38458943-107D7011-B2D0-4DCA-B847-E91419632D65 Q38639328-F62EBDD6-F0FE-426B-ABA2-A678800D3B13 Q38654045-4774ACAE-183F-419D-8730-115AD85644FB Q38993673-02134289-08E6-4083-8EB4-1514B21CECCB Q39629256-CA0ACF57-1794-4752-B53B-7CB737EF61EF Q40392188-E9A2E527-4B01-4926-A58B-EFCB5794822C Q41734464-2D9A7B3C-BF02-4C0B-96A6-0DA59CB9CE18 Q42577971-8EA7F48A-D1B4-4E60-97D5-45354BB2E226 Q43257519-1E31200A-CB91-48EC-8410-4ADAFE2F32E3 Q43314674-B4B21D6D-EA32-4EDD-89A0-9D2F3882DF82 Q44250471-310089C4-5472-4E56-A2DF-D33A304E33B6 Q45289637-3F830350-E0A2-4578-9572-D576CDBE1778 Q45289739-684CE737-62F5-4EEC-9674-48C3BA50D345 Q45290567-5821DC07-FD2B-4065-8ECD-203446B70CBB Q45292519-64BE3821-4C40-46F9-A50F-3883AF67FA3F Q49659203-3695C095-1D27-4A57-AF33-4FA7F478A25F Q55295842-08B7F996-89A5-4DF0-846F-02579B9A3A17

P2860

Increased metabolism in the R6/2 mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q33301810

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@ast

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@en

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@nl

type

label

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@ast

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@en

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@nl

prefLabel

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@ast

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@en

Increased metabolism in the R6/2 mouse model of Huntington's disease.

@nl

P1433

Q33301810-EA33FC14-5A25-49F9-8134-26E48E0849A8

P1476

Q33301810-B8B2B6E3-7147-490A-A1CB-2FE9B10919F2

P2093

Q33301810-1EB6457C-1108-40AC-8D9A-F2815CD96F71

Q33301810-6DE1BE33-2F4A-4A38-890B-E2EA06CC0A47

Q33301810-724CA474-E62D-4471-BEAD-AE3DF49190BD

Q33301810-782E12F9-A9EE-4133-ABFF-5E2C9B90BC3E

Q33301810-9A8FE427-C621-46A4-A35F-FA748C5164FF

Q33301810-B4B940D8-1626-43F9-AF28-5EF41D994522

Q33301810-B952CD29-8AEB-421F-A197-2C9041C59D05

Q33301810-BA3A8632-7CC3-4125-9899-8ECC2F6A4C91

Q33301810-C7B6C3D7-3439-4D73-BEC8-498C54393D9F

Q33301810-D2D62AEB-7D44-43B6-B20E-F00372436D68

P304

Q33301810-54F2856C-C955-4E91-85B7-E092837DA014

P31

Q33301810-1894A821-5D7D-4F64-9B4A-0457A5C74139

P356

Q33301810-096A39AC-610B-4107-BDF2-6ED75735835A

P433

Q33301810-E3F6F2E8-FA4D-4775-BF8C-B8BD48B12E3F

P478

Q33301810-981316BB-FB3B-41D6-B662-B6EB45AF7DF0

P50

Q33301810-2107D85A-BFDE-4464-B8C0-4358A90BA90D

Q33301810-726C51F0-4D81-417C-99A0-46B76410B451

Q33301810-72C60DD8-31DB-4EBD-A15A-FD4DFF3FA9D1

Q33301810-864E9B48-A62C-40FA-B159-316474267142

Q33301810-925130FD-40D4-48F6-A8D8-E7B93C57569F

Q33301810-A034F1B3-A020-4F93-882A-1D9EF0E845DC

Q33301810-AE4C2200-1624-43EE-8BB0-F70A55200668

P577

Q33301810-6E471C30-901D-45AE-A487-E4E9E074D27E

P5875

Q33301810-5DAB12E8-923E-4E97-803A-96E02A3371CA

P698

Q33301810-70A893C0-620F-492A-ABC5-2C4F76129AB7

P921

Q33301810-9292EEA9-1A1A-4104-9329-7262ABA8193C

P356

J.NBD.2007.07.029

P1433

Neurobiology of Disease

P1476

Increased metabolism in the R6/2 mouse model of Huntington's disease

@en

P2093

Andreas Lindqvist

http://www.w3.org/2001/XMLSchema#string

Asa Petersén

http://www.w3.org/2001/XMLSchema#string

Ben Woodman

http://www.w3.org/2001/XMLSchema#string

Jaclyn I Wamsteeker

http://www.w3.org/2001/XMLSchema#string

Jorien M M van der Burg

http://www.w3.org/2001/XMLSchema#string

Michael J Kuhar

http://www.w3.org/2001/XMLSchema#string

Nigel I Wood

http://www.w3.org/2001/XMLSchema#string

Nils Wierup

http://www.w3.org/2001/XMLSchema#string

Patrik Brundin

http://www.w3.org/2001/XMLSchema#string

Tomas Deierborg

http://www.w3.org/2001/XMLSchema#string

P304

41-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NBD.2007.07.029

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Erlanson-Albertsson

A Jennifer Morton

P577

2007-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5925369

http://www.w3.org/2001/XMLSchema#string

P698

17920283

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease